A gigantic wave of opportunity is rolling in, and Mangoceuticals, Inc. (NASDAQ:MGRX) is ready to ride its crest. The company, more popularly known as MangoRx, is geared up to conquer the Big Apple with its groundbreaking telemedicine platform, offering men’s health and wellness products.
In an exciting move, MangoRx is entering a robust partnership with the Greater NY Chamber of Commerce (GNYCC), an influential body representing an astounding 30,000+ business and civic leaders that form the lifeblood of the Greater New York area. The primary goal? Accelerate sales growth and discover fresh avenues for marketing its exemplary product range, notably the flagship erectile dysfunction drug, “Mango”.
**Why New York?**
The Empire State has always ranked among the top five U.S states in terms of erectile dysfunction medication sales. With its aptly named “Make America Hard Again” campaign, MangoRx’s decision to tap into the NY market is strategic and timely, aligning with the momentum they’ve gained nationally.
Jacob Cohen, CEO and Co-Founder of Mangoceuticals, expressed his enthusiasm: “Aligning with one of America’s biggest Chambers of Commerce marks a defining moment in our quest for heightened sales growth, brand visibility, and opening up new market channels. The existing brand rapport we enjoy in NY makes it a natural choice for a direct sales push for our flagship product.”
**The Power of Partnership**
The collaboration isn’t merely transactional. The Greater New York Chamber of Commerce is introducing a new Men’s Health & Wellness committee and has graciously provided all its 30,000 members complimentary access to Mango. These members span from budding entrepreneurs to foreign dignitaries, making the potential outreach vast and varied.
Backing this partnership, Mark Jaffe, the President and CEO of GNYCC remarked, “The entry of MangoRx in New York as an elite member comes with great expectations and optimism. We’re confident that this is just the beginning of a fruitful journey for both MangoRx and GNYCC.”
**Statistics Speak**
The scope is massive, with North America holding the lion’s share in the global erectile dysfunction drugs market in 2022, and the U.S. sexual wellness domain clocking in a whopping USD 11.0 billion valuation the same year. Projections from Grand View Research hint at a stellar growth rate of 7.91% CAGR from 2023 to 2030.
**Marching Ahead**
MangoRx isn’t just banking on a single partnership. Their aggressive growth blueprint encompasses collaborations with big names, including the award-winning Lucky Break PR firm. The company also flaunts sponsorship deals with men’s demographic leaders like Barstool Sports, Only Stans, Pillow Talk, and No Jumper. The nationwide launch of the “Make America Hard Again” campaign adds another feather to their cap.
As the world watches, MangoRx’s next launch promises to be a game-changer – a new sildenafil-based Mango ED product, equipped with the active ingredient in Viagra™. Given their trajectory and the powerhouse partnership with GNYCC, the future looks promising not just for MangoRx, but for the entire realm of men’s health and wellness.
Stay tuned for what promises to be a riveting chapter in the evolution of men’s healthcare!
Some of the biggest analyst calls for Wednesday include Wednesday’s biggest analyst calls: Nvidia (NASDAQ:NVDA), Rivian (NASDAQ:RIVN), Peloton (NASDAQ:PTON), UPS, Eli Lilly and DraftKings (NASDAQ:DKNG)
Source: https://finance.yahoo.com/news/mangoceuticals-partners-greater-ny-chamber-120000002.html
Disclaimer: Please make sure to read and completely understand our disclaimer at InvestorBrandMedia.com/Disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. InvestorBrandMedia.com strongly recommends you consult a licensed or registered professional before making any investment decision. Neither InvestorBrandMedia.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. InvestorBrandMedia.com often gets compensated for advertisement services that are disclosed on our disclaimer located at InvestorBrandMedia.com/Disclaimer. We have been compensated for advertisement services on MGRX by a 3rd party.
